You are here

  • Home
  • Archive
  • Volume 63, Issue 9
  • Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Citation Tools

Article menu
Download PDFPDF
Inflammatory bowel disease
Original article
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
van Bodegraven AA, Bravenboer N, Witte BI on behalf of the Dutch Initiative on Crohn and Colitis (ICC), et al
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation
Gut 2014;63:1424-1430.